Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012

Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs

Michael L. Jackson1Comments to Author , Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 1

Figure 1. Structure of Haemophilus influenzae type b (Hib) simulation model. Persons are born into the no-antibody, disease-susceptible state and can die in any of the model states. Hib-susceptible persons become colonized based on the force of infection (FOI), which is reduced by protection from low (VEL,C) or high (VEH,C) antibody levels. Persons colonized with Hib develop invasive disease, which is reduced by protection from low (VEL,D) or high (VEH,D) antibody levels. Colonized and diseased persons recover to the high-antibody, disease-susceptible state. As immunity wanes, susceptible persons move from high to low antibody and from low to no antibody. Some persons are vaccinated and move from no or low antibody states to the high antibody state. For the Alaska Native population, use of bacterial polysaccharide immunoglobulin (BPIG) starting at birth temporarily moves persons to an immune state; as BPIG wanes, immune persons return to the susceptible state. See Technical Appendix 1 for a formal description of the model structure.

Main Article

1Current affiliation: Group Health Research Institute, Seattle, Washington, USA.

Page created: December 21, 2011
Page updated: December 21, 2011
Page reviewed: December 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.